{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-26-000744","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2026-05-15T20:15:25+00:00","discovered_at":"2026-05-15T20:22:00.616020+00:00","generated_at":"2026-05-15T20:22:19.087816+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Anavex COO Felix Lauscher departs May 11 amid reorganization after interim CEO","bullets":["Felix Lauscher, COO since March 1, 2026, left Anavex on May 11, 2026.","Departure part of broader reorganization after appointing Dr. Terrie Kellmeyer as Interim CEO.","Lauscher had $264K annual base salary; received prorated pay for service period.","Of 50,000 stock options granted, 45,833 forfeited; 4,167 vested at $4.69/share exercisable until Aug 9, 2026.","Offered two weeks' additional compensation at base salary in exchange for general release."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000744","json":"https://secwatch.observer/filing/0001731122-26-000744.json","markdown":"https://secwatch.observer/filing/0001731122-26-000744.md","text":"https://secwatch.observer/filing/0001731122-26-000744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000744/0001731122-26-000744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000744/e7648_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T20:22:19.087816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57425d83e6","claim":"Felix Lauscher departed as Chief Operating Officer at ANAVEX LIFE SCIENCES CORP..","evidence_excerpt":"On May 11, 2026, Felix Lauscher, who had held the title of Chief Operating Officer of Anavex Life Sciences Corp. (the “Company”) since March 1, 2026, departed from the Company as part of a broader reorganization of duties at the Company following the appointment of Dr. Terrie Kellmeyer as the Company’s Interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000744/0001731122-26-000744-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}